ELDN
What one share of Eledon Pharmaceuticals holds
Pharmaceutical Preparations
Eledon is a clinical stage biotechnology company using our immunology expertise in targeting the CD40 Ligand (“CD40L”) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (“ALS”).
Eledon Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.93 |
|---|---|
| Cash and investments | $0.08 |
| Debt | $0.00 |
| Book value | $0.41 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2012 | $0.00 | −$31.09 | $0.03 | −$29.99 | — | −$128.10 |
| 2013 | $0.00 | −$38.02 | $0.06 | −$37.25 | — | −$112.04 |
| 2014 | $0.00 | −$3.60 | $0.00 | −$3.27 | — | — |
| 2015 | $0.00 | −$2.01 | $0.03 | −$1.86 | — | $0.12 |
| 2018 | — | −$1.56 | — | −$1.32 | — | $1.54 |
| 2019 | — | −$24.42 | — | −$21.14 | — | $13.14 |
| 2020 | — | −$15.72 | — | −$10.48 | — | — |
| 2021 | — | −$2.33 | — | −$1.95 | — | $11.46 |
| 2022 | — | −$6.16 | — | −$1.99 | — | $1.73 |
| 2023 | — | −$4.73 | — | −$1.61 | — | −$2.00 |
| 2024 | — | −$0.66 | — | −$0.97 | — | $1.04 |
| 2025 | — | −$0.52 | — | −$0.76 | — | $1.07 |